- ►pharmyaring.com [PDF] SE Inzucchi - Jama, 2002 - Am Med Assoc Context Care of patients with type 2 diabetes has been revolutionized throughout
the past several years—first, by the realization of the importance of tight
glycemic control in forestalling complications, and second, by the ... Cited by 601 - Related articles - BL Direct - All 18 versions
A Dornhorst - The Lancet, 2001 - Elsevier The loss of early-phase insulin secretion is an important and early event in the
natural history of type 2 diabetes. Because a normal pattern of insulin
secretion is essential for the effective control of postprandial ... Cited by 105 - Related articles - BL Direct - All 5 versions
- ►adisonline.com [PDF] M Rendell - Drugs, 2004 - ingentaconnect.com The sulphonylureas act by triggering insulin release from the pancreatic β
cell. Abstract A specific site on the adenosine triphosphate (ATP)-sensitive
potassium channels is occupied by sulphonylureas leading to closure of the ... Cited by 87 - Related articles - BL Direct - All 7 versions
G Derosa, A Mugellini, L Ciccarelli, G … - Clinical therapeutics, 2003 - Elsevier Methods: This randomized, placebo-controlled, double-blind trial was conducted
at a single center in Italy. Eligible patients were nonsmokers; had no
hypertension or coronary heart disease; were taking no hypolipidemic drugs, ... Cited by 51 - Related articles - All 5 versions
L Van Gaal, I De Leeuw - Diabetologia, 2003 - Springer Pharmacological therapy for Type 2 (non-insulin-de- pendent) diabetes mellitus
aims at controlling hyper- glycaemia to delay or prevent complications associat-
ed with the disease. Most patients with Type 2 diabe- tes present with both ... Cited by 50 - Related articles - BL Direct - All 4 versions
- ►columbiauniversity.org [PDF] B Kimmel, SE Inzucchi - Clinical Diabetes, 2005 - Am Diabetes Assoc Type 2 diabetes is a multifactorial metabolic disease characterized by
abnormalities at multiple organ sites. These defects include insulin resistance
and insulin deficiency. 1,2 The former is primarily represented by ... Cited by 46 - Related articles - All 5 versions
L Jovanovic, DR Hassman, B Gooch, R Jain, … - Diabetes research and clinical practice, 2004 - Elsevier The efficacy and safety of combination therapy (repaglinide plus pioglitazone)
was compared to repaglinide or pioglitazone in 24-week treatment of type 2
diabetes. This randomized, multicenter, open-label, parallel-group study ... Cited by 38 - Related articles - All 4 versions
- ►smh.com [PDF] J Albu, N Raja-Khan - Primary Care: Clinics in Office Practice, 2003 - Elsevier Obesity is a major worldwide epidemic that is associated with a significantly
increased risk of type 2 diabetes, cardiovascular disease, and premature death
[1 and 2]. Obesity is associated with increased mortality, especially when ... Cited by 38 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org J Rosenstock, SG Shen, MR Gatlin, JE Foley - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—At the 16-week end point, nateglinide 120 mg, troglitazone 600 mg, and
the combination of the agents achieved statistically significant decreases in
HbA 1c in comparison with placebo and a baseline HbA 1c of 8.1–8.4% (P < ... Cited by 36 - Related articles - BL Direct - All 7 versions
